Study Finds Blue Light Cystoscopy Cost-Neutral in Bladder Cancer Care

Researchers analyzed claims data from the U.S. Optum Research Database, comparing 794 patients who underwent blue light cystoscopy (BLC) against 4,764 patients treated with white light cystoscopy (WLC) between 2011 and 2023. While BLC patients recorded more ambulatory visits and biomarker testing, the economic analysis revealed no statistically significant difference in costs. Total healthcare expenses per patient per month averaged $2,987.93 for the BLC cohort and $2,886.16 for the WLC group.

Principal investigator Mark Tyson noted that the findings reinforce the clinical utility of the diagnostic tool. By improving the detection of carcinoma in situ, BLC facilitates more frequent monitoring, yet the data confirms this approach remains cost-neutral. The study indicates that optimizing early diagnostic accuracy through advanced imaging can support patient outcomes without placing additional financial strain on the healthcare system.